We thank Lori R. Anderson for help typing and submitting the manuscript; Kaiser Lim, M.D., Prasad Iyer, M.D., Adil A. Abdalla, M.B.B.S. and Judith McElhiney, M.D., for help recruiting subjects; Rayna M. Grothe, M.D., Joanna M. Peloquin, M.D., Shabana F. Pasha, M.D., and Darlene E. Graner, CCC-SLP, for help conceptualizing the study design; and Michael D. Van Norstrand, M.D., Ph.D., for editorial assistance. The project was supported in part by the Miles and Shirley Fiterman Center for Digestive Diseases at Mayo Clinic, Rochester, Minnesota. Yvonne Romero, M.D., was supported in part by a grant from the National Institutes of Health (NIDDK 02956) and the Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Program.
Conflict of interest
This study was funded in part by an Investigator-Initiated Research Award from Santarus, Inc., IRB # 07-008503. Santarus Inc. provided study medications [omeprazole/sodium bicarbonate (Zegerid®) and Gelusil™] at no charge. No assistance for manuscript preparation was received from Santarus, Inc. Unpaid academicians voluntarily wrote this paper. All data analysis was undertaken by Felicity T. Enders, Diana M. Orbelo, Nancy N. Diehl, Debra M. Geno, Yvonne Romero, David A. Katzka, Dawn L. Francis, Michael D. Crowell, Sami R. Achem, Ramona DeJesus, Vikneswaran Namasivayam, Steven C. Adamson, Amindra S. Arora, Andrew J. Majka, Jeffrey A. Alexander, Joseph A. Murray, Kee Wook Jung, Margaret S. Houston and Angela O’Neil, all of whom are or were Mayo Clinic employees at the time. Santarus Inc. provided salary support to FTE, NND, and DMG for data analysis, and DMG and MF for data collection. The Santarus study sponsors, William F. Bleker, M.D., Philip Yeung, Pharm.D., Gregg Checani, M.D., and E. David Ballard, M.D., participated in study design but did not participate in data collection, analysis or interpretation, and did not participate in drafting the manuscript or in the decision to publish the results of this trial. Study sponsors were permitted to review the manuscript prior to its submission for publication. Yvonne Romero has received research funding from Aptalis, AstraZeneca, Meritage Pharma and Takeda, has served as an ad hoc consultant for Kala, and receives royalties from the licensed use of the Mayo Dysphagia Questionnaire—30 day. Dawn L. Francis has received research funding from AstraZeneca, and receives royalties from the licensed use of the Mayo Dysphagia Questionnaire—30 day. Jeffrey A. Alexander has received research funding from Aptalis and Merck, serves as a consultant and has stock holdings of Meritage Pharma and receives royalties from the licensed use of the Mayo Dysphagia Questionnaire—30 day. Joseph A. Murray has an ownership interest with Torax Medical Inc. and Vysera Biomedical, and receives royalties from the licensed use of the Mayo Dysphagia Questionnaire—30 day. Felicity T. Enders, Michael D. Crowell, Debra M. Geno, Matthew Lohse, Nancy N. Diehl, and Mary Fredericksen receive royalties from the licensed use of the Mayo Dysphagia Questionnaire—30 day.